Gnosis launches Advanced Nutrition Platform

October, 28th 2014

Gnosis is proud to announce the launch of the Advance Nutrition Platform.

 

Gnosis wins big on folates

July, 14th 2014

Click here to see the latest news on Gnosis folates

 

Gnosis receives CEP certification for Teicoplanin

May, 28th 2014

The European Directorate for the Quality of Medicines (EDQM) has granted Gnosis a Certificate of Suitability of the European Pharmacopoeia (CEP) for Teicoplanin. The CEP certification provides proof that the quality of the substances used in human...

 

Gnosis obtains US FDA approval for its API Manufacturing Facility in Pisticci

May, 14th 2014

Gnosis announced US FDA approval for its API Manufacturing facility in Pisticci, Italy. Pisticci facility also received quality approval from Italian Moh and EMEA. This state-of-the-art facility is engaged in the development and manufacturing...

 

Gnosis achieved US FDA approval for its Manufacturing Facility in Switzerland

April, 8th 2014

Gnosis is pleased to announce that its Manufacturing Facility based in Sant’Antonino, Switzerland has received U.S. Food and Drug Administration (FDA) approval...

 

Quatrefolic® receives Novel Food approval

March, 31st 2014

Gnosis is pleased to announce that on March 19th, 2014 the European Commission approved the use of Quatrefolic® in the European Union as a Novel Food Ingredient to be used in food supplements. This opens the way for the commercialization of Quatrefolic in the 28 EU-member state market to Quatrefolic®...

 

< Turn back

 

 

 

 

GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151